Exelixis, Inc. financial data

Symbol
EXEL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1851 Harbor Bay Parkway, Alameda, California
State of incorporation
Delaware
Fiscal year end
January 3
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 371 % -28.2%
Quick Ratio 5.64 % -38.5%
Debt-to-equity 29.8 % +32.8%
Return On Assets 12.2 % +128%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 285M shares -10.4%
Common Stock, Shares, Outstanding 285M shares -10.9%
Entity Public Float 4.7B USD -31.2%
Common Stock, Value, Issued 285K USD -10.9%
Weighted Average Number of Shares Outstanding, Basic 289M shares -10.8%
Weighted Average Number of Shares Outstanding, Diluted 294M shares -10.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.01B USD +17.5%
Research and Development Expense 1.02B USD +1.36%
Costs and Expenses 1.64B USD +4.54%
Operating Income (Loss) 370M USD +162%
Income Tax Expense (Benefit) 101M USD +124%
Net Income (Loss) Attributable to Parent 350M USD +113%
Earnings Per Share, Basic 1.18 USD/shares +131%
Earnings Per Share, Diluted 1.17 USD/shares +134%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 198M USD -57.3%
Inventory, Net 20.6M USD -28%
Assets, Current 1.48B USD -7.11%
Deferred Income Tax Assets, Net 362M USD +56.4%
Property, Plant and Equipment, Net 130M USD +13.2%
Operating Lease, Right-of-Use Asset 233M USD -0.67%
Goodwill 63.7M USD 0%
Other Assets, Noncurrent 280M USD +108%
Assets 2.77B USD -11.8%
Accounts Payable, Current 28.7M USD +10.3%
Contract with Customer, Liability, Current 3.44M USD -49.4%
Liabilities, Current 346M USD +1.79%
Contract with Customer, Liability, Noncurrent 4.42M USD -34.3%
Operating Lease, Liability, Noncurrent 198M USD +1.71%
Other Liabilities, Noncurrent 110M USD +49.2%
Liabilities 653M USD +6.32%
Accumulated Other Comprehensive Income (Loss), Net of Tax -5.15M USD +64.3%
Retained Earnings (Accumulated Deficit) -200M USD -1888%
Stockholders' Equity Attributable to Parent 2.12B USD -16.1%
Liabilities and Equity 2.77B USD -11.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 68.8M USD -18.5%
Net Cash Provided by (Used in) Financing Activities -184M USD -4113%
Net Cash Provided by (Used in) Investing Activities 112M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 285M shares -10.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.43M USD -109%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 198M USD -57.3%
Deferred Tax Assets, Valuation Allowance 83M USD +7.47%
Deferred Tax Assets, Gross 498M USD +37.9%
Operating Lease, Liability 216M USD +3.77%
Payments to Acquire Property, Plant, and Equipment 9.69M USD -19.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 359M USD +126%
Lessee, Operating Lease, Liability, to be Paid 316M USD -1.18%
Property, Plant and Equipment, Gross 209M USD +21.9%
Operating Lease, Liability, Current 25.7M USD +45.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 25.6M USD +8.16%
Lessee, Operating Lease, Liability, to be Paid, Year One 26.3M USD +45.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 79.3M USD -10.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 26.2M USD +13.3%
Deferred Tax Assets, Operating Loss Carryforwards 29.5M USD -12.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 116M USD +32%
Lessee, Operating Lease, Liability, to be Paid, Year Four 27M USD +14.2%
Additional Paid in Capital 2.32B USD -8.15%
Depreciation, Depletion and Amortization 6.38M USD -6.96%
Deferred Tax Assets, Net of Valuation Allowance 415M USD +46.2%
Share-based Payment Arrangement, Expense 109M USD +4.29%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%